Document is current
Any future updates will be listed below
-
Authors
Abel, Mary Kathryn
Shui, Amy M. https://orcid.org/0000-0002-8243-6910
Melisko, Michelle
Chien, A. Jo
Yoshida, Emi J.
Lancaster, Elizabeth M.
Van ‘T Veer, Laura https://orcid.org/0000-0002-9838-8298
Esserman, Laura J. https://orcid.org/0000-0001-9202-4568
Mukhtar, Rita A. https://orcid.org/0000-0001-8079-7846
- License Information
-
More Information
Article History
Received: 13 July 2021
Accepted: 6 December 2021
First Online: 21 December 2021
Competing interests
: M.M. receives research funding from Astra Zeneca, Novartis, KCRN Research, and Puma and consulting fees from Biotheranostics. A.J.C. receives research funding from Merck, Puma, Amgen, and Seattle Genetics. L.J.E. is an unpaid member of the board of directors of Quantum Leap Healthcare Collaborative and receives research funding from QLHC for the I-SPY TRIAL. She is a member of the Blue Cross/Blue Shield Medical Advisory Panel and receives honoraria and travel funding. She has a grant from Merck for an Investigator initiated trial of DCIS. L.V.T.V. is a co-inventor of the MammaPrint signature and a co-founder and stockholder in Agendia, Inc. The rest of the authors declare no competing interests.
